2019 Consensus Korean Diagnostic Guidelines to Define Severity Classification and Treatment Refractoriness for Atopic Dermatitis: Objective and Subjective Assessment of Severity.

Autor:	Kim JE; Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea., Shin MK; Department of Dermatology, Kyung Hee University College of Medicine, Seoul, Korea., Park GH; Department of Dermatology, Hallym University College of Medicine, Chuncheon, Korea., Lee UH; Department of Dermatology, Inje University Sanggye Paik Hospital, Inje University, Seoul, Korea., Lee JH; Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea., Han TY; Department of Dermatology, Nowon Eulji Medical Center, Eulji University, Seoul, Korea., Koh HC; Department of Dermatology, Pusan National University School of Medicine, Busan, Korea., Jang YH; Department of Dermatology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea., Kim HO; Department of Dermatology, Hallym University College of Medicine, Chuncheon, Korea., Na CH; Department of Dermatology, College of Medicine, Chosun University, Gwangju, Korea., Lew BL; Department of Dermatology, Kyung Hee University College of Medicine, Seoul, Korea., Ahn JY; Department of Dermatology, National Medical Center, Seoul, Korea., Park CO; Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea., Seo YJ; Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea., Lee YW; Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea.; Research Institute of Medical Science, Konkuk University, Seoul, Korea., Sohn SW; Department of Dermatology, Korea University College of Medicine, Seoul, Korea., Park YL; Department of Dermatology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Jazyk:	angličtina
Zdroj:	Annals of dermatology [Ann Dermatol] 2019 Dec; Vol. 31 (6), pp. 654-661. Date of Electronic Publication: 2019 Oct 31.
DOI:	10.5021/ad.2019.31.6.654
Abstrakt:	Background: Systemic immunomodulatory treatment is actively recommended in the treatment for moderate to severe atopic dermatitis (AD) patients. However, consensus criteria for the classification of AD severity or treatment refractoriness have not been established yet. Objective: To establish consensus criteria on the definition of severity classification and treatment refractoriness of AD to provide a basis for proper treatment strategy. Methods: The Korean Atopic Dermatitis Association (KADA) comprised a task force team to establish a definition of moderate to severe AD. A draft of definition of moderate to severe AD was made on the basis of evidence. The recommendation was confirmed by KADA members through a web-based survey. Results: KADA approved that AD with 16≤eczema area and severity index (EASI)<23 should be basically defined as moderate AD whereas AD with EASI score ≥23 should be considered as severe AD. They agreed that it would be reasonable to raise the severity level if patient's daytime or nighttime pruritus numerical rating scale is equal to or higher than 7 (≥7) or dermatology life quality index score exceeds 10. AD patients who do not reach EASI 50 after appropriate treatment for three months should be considered as a non-responder. Patients with recurrence (EASI ≥16) within three months after cessation of treatment should be considered as a recurrent AD. Conclusion: KADA built a consensus of definition of moderate and severe AD and treatment-refractoriness. These guidelines are expected to help physicians determine proper treatment options in need. Competing Interests: CONFLICTS OF INTEREST: The authors have nothing to disclose. (Copyright © 2019 The Korean Dermatological Association and The Korean Society for Investigative Dermatology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu